Tags

Type your tag names separated by a space and hit enter

Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Mult Scler Relat Disord 2019; 35:270-271MS

Abstract

Alemtuzumab is an anti-CD52 monoclonal antibody approved for the treatment of multiple sclerosis (MS). It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution.

Authors+Show Affiliations

Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain. Electronic address: claraguih@hotmail.com.Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain.Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain.Department of Neurology, Hospital Universitario La Princesa, 28002 Madrid, Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31442904

Citation

Aguirre, Clara, et al. "Cytomegalovirus Primary Infection in a Patient With Multiple Sclerosis Treated With Alemtuzumab." Multiple Sclerosis and Related Disorders, vol. 35, 2019, pp. 270-271.
Aguirre C, Meca-Lallana V, Sánchez P, et al. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab. Mult Scler Relat Disord. 2019;35:270-271.
Aguirre, C., Meca-Lallana, V., Sánchez, P., & Vivancos, J. (2019). Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab. Multiple Sclerosis and Related Disorders, 35, pp. 270-271. doi:10.1016/j.msard.2019.07.026.
Aguirre C, et al. Cytomegalovirus Primary Infection in a Patient With Multiple Sclerosis Treated With Alemtuzumab. Mult Scler Relat Disord. 2019 Aug 6;35:270-271. PubMed PMID: 31442904.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab. AU - Aguirre,Clara, AU - Meca-Lallana,Virginia, AU - Sánchez,Pedro, AU - Vivancos,Jose, Y1 - 2019/08/06/ PY - 2019/02/10/received PY - 2019/06/18/revised PY - 2019/07/27/accepted PY - 2019/8/24/pubmed PY - 2019/8/24/medline PY - 2019/8/24/entrez SP - 270 EP - 271 JF - Multiple sclerosis and related disorders JO - Mult Scler Relat Disord VL - 35 N2 - Alemtuzumab is an anti-CD52 monoclonal antibody approved for the treatment of multiple sclerosis (MS). It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution. SN - 2211-0356 UR - https://www.unboundmedicine.com/medline/citation/31442904/Cytomegalovirus_primary_infection_in_a_patient_with_multiple_sclerosis_treated_with_alemtuzumab L2 - https://linkinghub.elsevier.com/retrieve/pii/S2211-0348(19)30320-7 DB - PRIME DP - Unbound Medicine ER -